drugset / Trial / NCT07179783
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
Phase 2
Recruiting
28 enrolled
Tianjin Medical University Second Hospital
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment of AVPC (aggressive variant prostate cancer) and NEPC (neuroendocrine prostate cancer).
Timeline
- Start
- 2025-09-22
- Primary completion
- 2027-06-30
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KL-A167 | Unknown | 900 mg | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 5 mg/kg | Intravenous |